JP5013325B2 - Liquid composition - Google Patents

Liquid composition Download PDF

Info

Publication number
JP5013325B2
JP5013325B2 JP2000315975A JP2000315975A JP5013325B2 JP 5013325 B2 JP5013325 B2 JP 5013325B2 JP 2000315975 A JP2000315975 A JP 2000315975A JP 2000315975 A JP2000315975 A JP 2000315975A JP 5013325 B2 JP5013325 B2 JP 5013325B2
Authority
JP
Japan
Prior art keywords
liquid composition
cyanine dye
aqueous medium
oxygen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000315975A
Other languages
Japanese (ja)
Other versions
JP2002121416A (en
JP2002121416A5 (en
Inventor
美典 中川
豊志子 須田
均 堀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority to JP2000315975A priority Critical patent/JP5013325B2/en
Priority to KR1020010063186A priority patent/KR20020030022A/en
Publication of JP2002121416A publication Critical patent/JP2002121416A/en
Publication of JP2002121416A5 publication Critical patent/JP2002121416A5/ja
Application granted granted Critical
Publication of JP5013325B2 publication Critical patent/JP5013325B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Description

【0001】
【発明の属する技術分野】
本発明は有機色素化合物を含有する組成物に関するものであり、詳細には、シアニン色素を含有する安定な液状組成物に関するものである。
【0002】
【従来の技術】
疾病を惹起する根本的な原因としては、微生物感染、化学物質への接触、放射線への被爆、生活環境、生活習慣、老化、遺伝的要素などが挙げられるが、斯かる病因に対する生体の反応は様々である。例えば、微生物感染の場合、微生物が侵入したすべての生体が感染症を惹起するわけではなく、また、感染症の治療に際して、同様の治療を受けている患者同士であっても、回復の状況や副作用が有意に異なることがある。その原因の一つとして、生体の活力が細胞レベルで低下していることが考えられ、生体の活力が細胞レベルで低下していると、当然のことながら、健康の回復が遅れたり、薬剤の副作用が強く顕現することとなる。細胞賦活剤は、斯かる患者を対象として、必要に応じて、他の薬剤と併用することによって、病因に対する生体の抵抗力や回復力を細胞レベルで昂進するための薬剤である。細胞賦活剤としては、現在、クロロフィル製剤、色素製剤、核酸製剤、アミノ酸製剤、動植物の抽出物などが用いられており、このうち、色素製剤は、低用量で著効を発揮し、しかも、作用が穏やかで、長期間連用しても重篤な副作用を惹起しないことから、熱傷及び難治性皮膚潰瘍を中心に1940年代から用いられている。
【0003】
色素製剤は、対象となる疾患や症状などに応じて、皮内、筋肉内又は静脈内へ注射投与される。現在、色素製剤はシアニン色素を含有する乾燥注射剤の形態のものだけが市販されているが、液状製剤が入手できないのは、シアニン色素が水性媒体中で不安定であることによるとされている。シアニン色素の乾燥注射剤は、水性媒体におけるシアニン色素の溶解度が比較的小さいことから、使用に先立って、臨床現場において所定の濃度の溶液に調製するのに手間が掛かるという問題があった。
【0004】
【発明が解決しようとする課題】
斯かる状況に鑑み、この発明の課題は、シアニン色素を含有する安定な液状組成物を提供することにある。
【0005】
【課題を解決するための手段】
この課題を解決すべく、本発明者が鋭意研究し、検索したところ、水性媒体においてシアニン色素が不安定であるのは、共存する酸素が原因であることを突き止めた。そこで、本発明者がシアニン色素の液状組成物における酸素濃度に着目し、溶存酸素の濃度が相違する種々の液状組成物を調製するとともに、これらを一定時間放置した後、残存するシアニン色素を測定したところ、溶存酸素の濃度が水性媒体の常温常圧の大気環境下における酸素濃度を下回る液状組成物においては、シアニン色素が分解し難く、比較的長期間に亙って安定に存在することを見出した。
【0006】
すなわち、この発明は、上記の課題を、特定のシアニン色素と、そのシアニン色素を溶解する水性媒体とを含んでなり、溶存酸素の濃度がその水性媒体の常温常圧の大気環境下における酸素濃度を下回る液状組成物を提供することによって解決するものである。
【0007】
さらに、この発明は、上記の課題を、特定のシアニン色素を水性媒体に溶解する工程と、該水性媒体をしてその常温常圧の大気環境下における酸素濃度を下回らせる工程とを経由する液状組成物の製造方法を提供することによって解決するものである。
【0008】
【発明の実施の形態】
既述のとおり、この発明は、一般式1で表されるシアニン色素(以下、単に「シアニン色素」と言うことがある。)と、シアニン色素を溶解する水性媒体とを含んでなり、溶存酸素の濃度がその水性媒体の常温常圧の大気環境下における酸素濃度を下回る液状組成物に関するものである。
【0009】
【化2】

Figure 0005013325
【0010】
一般式1において、Rは脂肪族炭化水素基を表す。Rにおける脂肪族炭化水素基としては、通常、炭素数が1乃至12であるものが選択され、個々の脂肪族炭化水素基としては、例えば、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、イソブチル基、sec−ブチル基、tert−ブチル基、ペンチル基、イソペンチル基、tert−ペンチル基、1−メチルペンチル基、2−メチルペンチル基、ヘキシル基、イソヘキシル基、5−メチルヘキシル基、ヘプチル基、オクチル基、ノニル基、デシル基、ウンデシル基、ドデシル基などが挙げられる。一般式1におけるX-は適宜の対イオンであり、通常、例えば、弗素イオン、塩素イオン、臭素イオン、沃素イオン、過塩素酸イオン、過沃素酸イオン、六弗化燐酸イオン、六弗化アンチモン酸イオン、六弗化錫酸イオン、燐酸イオン、硼弗化水素イオン、四弗硼素酸イオンなどの無機酸アニオンや、チアシアン酸イオン、ベンゼンスルホン酸イオン、ナフタレンスルホン酸イオン、ナフタレンジスルホン酸イオン、p−トルエンスルホン酸イオン、アルキルスルホン酸イオン、ベンゼンカルボン酸イオン、アルキルカルボン酸イオン、トリハロアルキルカルボン酸イオン、アルキル硫酸イオン、トリハロアルキル硫酸イオン、ニコチン酸イオン、アスパラギン酸イオンなどの有機酸アニオンから選択される。このうち、注射剤として用いられる液状組成物におけるシアニン色素としては、Rの炭素数が4乃至10、とりわけ、炭素数6乃至8のものが細胞膜への親和性が大きいので特に好ましい。また、対イオンが沃素イオンであるシアニン色素は、沃素イオンが生体内で殺菌作用を発揮する特徴がある。一般式1で表されるシアニン色素の具体例としては、例えば、化学式1乃至化学式3で表されるものが挙げられ、これらは、いずれも、この発明において極めて有利に用いることができる。
【0011】
【化3】
Figure 0005013325
【0012】
【化4】
Figure 0005013325
【0013】
【化5】
Figure 0005013325
【0014】
この発明でいう水性媒体とは、水を必須の要素とし、必要に応じて、これに、例えば、メタノール、エタノール、プロパノール、イソプロパノールなどのアルコール類、アセトンなどのケトン類、ジエチルエーテルなどのエーテル類、ジメチルスルホキシドなどの含硫化合物をはじめとする親水性有機溶剤の1又は複数を配合してなる水性媒体一般を意味する。この発明による注射剤における水性溶剤としては、注射用精製水を単独で用いるか、あるいは、注射用精製水と、例えば、エタノール、プロパノール、イソプロパノール、ジエチルエーテル、ジメチルスルホキシドなどの生理学的に許容される親水性有機溶剤との混液を用いるのが望ましい。
【0015】
この発明でいう液状組成物とは、斯かる水性媒体に一般式1で表されるシアニン色素を1又は複数溶解してなり、かつ、水性媒体に溶存する酸素の濃度がその常温常圧の大気環境下における酸素濃度を下回る範囲、通常、8ppm以下、望ましくは、0.4ppm以下、さらに望ましくは、0.1ppm以下に設定される。斯かる酸素濃度の液状組成物は、調製又は保存に際して、自然光や人工光などの環境光へ露光しても、シアニン色素が分解し難い。とりわけ、酸素濃度が0.1ppm以下である液状組成物は、環境光を遮断しない条件で長期間保存しても、酸素が遮断されているかぎり、シアニン色素がほとんど分解しない。
【0016】
斯かる液状組成物は、通常、シアニン色素を水性媒体に溶解する工程と、該水性媒体をしてその常温常圧の大気環境下における酸素濃度を下回らせる工程とを経由するこの発明による製造方法により調製することができる。シアニン色素を水性媒体に溶解するには、例えば、所定の量のシアニン色素を適量の水性媒体へ添加し、必要に応じて、加熱・攪拌しながら溶解させた後、必要に応じて、シアニン色素の濃度が所定のレベルになるまで水性媒体を追加する。この発明による液状組成物は、この発明の目的を逸脱しない範囲で、シアニン色素とともに、用途に応じたそれ以外の薬剤、細胞賦活剤に汎用されるビタミン類、アミノ酸類、浸透圧調節剤、緩衝剤、さらには、脱酸素剤などを配合することを妨げない。
【0017】
水性媒体をしてその常温常圧の大気環境下における酸素濃度を下回らせるには、例えば、液状組成物を減圧下で調製し、保存するか、液状組成物に溶存する酸素を別の気体で置換するか、あるいは、液状組成物を脱酸素剤へ接触させる方法が好適である。液状組成物に溶解する酸素を別の気体で置換するには、液状組成物中で、例えば、窒素などの比較的不活性な気体か、あるいは、ネオン、アルゴン、クリプトン、キセノンなどの希ガスをバブリングさせればよい。脱酸素剤を用いて酸素濃度を下げるには、液状組成物へ、例えば、L−アスコルビン酸、L−アスコルビン酸ステアリン酸エステル、亜硫酸ナトリウム、亜硫酸水素ナトリウム、アルファチオグリセリン、エデト酸ナトリウム、塩酸システイン、クエン酸、大豆レシチン、チオグリコール酸ナトウム、チオリンゴ酸ナトリウム、ピロ亜硫酸ナトリウム、ブチルヒドロキシアニソールなどを適量添加すればよい。これらの方法は、シアニン色素を含有する液状組成物へ適用しても、シアニン色素を溶解する前の水性媒体へ適用してもよい。
【0018】
斯くして得られた液状組成物は、酸素を遮断し得る、用途に応じた適宜の容器へ封入した状態で保存される。容器の材質としては、原理上、液状組成物を保持することができ、かつ、酸素を実質的に遮断し得るものであるかぎり、特に制限がない。用途にもよるけれども、通常、ガラスアンプル、バイアル瓶などの容器へ液状組成物を分注し、封止した後、高圧滅菌などにより滅菌する。
【0019】
この発明による液状組成物の使用方法について説明すると、この発明による液状組成物は、自然光、人工光などの環境光へ長期間露光してもシアニン色素が分解し難いことから、医療分野をはじめとする種々の分野で極めて有用である。最も重要な用途は医療の分野にあり、この発明の液状組成物による注射剤は、外科、成形外科、形成外科、放射線科、内科、神経科、神経内科、小児科、呼吸器科、産婦人科、耳鼻咽喉科、皮膚科、泌尿器科、眼科、麻酔科、歯科などの医療分野において、単独又は他の治療剤、予防剤と併用して、生体における免疫系、造血系、内分泌系、循環器系、消化器系、神経系を細胞レベルで賦活する。さらに、この発明による注射剤は、生体膜における脂質成分が酸化されるのを抑制する作用がある。医療の分野以外の分野における用途としては、化学及び分析化学の分野において、シアニン色素の収量や分析精度の向上にも著明な効果を発揮する。なお、医療分野において、この発明による液状組成物を注射剤として用いる場合、用法、用量は従来公知のものに準じて設定する。
【0020】
以下、この発明の実施の形態につき、実施例に沿って説明する。
【0021】
【実施例】
〈液状組成物〉
注射用精製水200gにグルコース15gを溶解してなる溶液と、注射用精製水85gに化学式3で表されるプラトニン類15mgを溶解してなる溶液とを混合して液状組成物となし、溶存する酸素の濃度が約0.1ppmになるまで窒素ガスをバブリングし、褐色アンプルに1mlずつ分注し、窒素気流下でアンプルを封止した後、高圧滅菌した。定法により測定したところ、本例の液状組成物における酸素濃度は0.097ppmであった。
【0022】
比較のために、バブリング時間を短かくするか、バブリングを省略することによって、溶存酸素の濃度が0.47ppm、0.49ppm又は8.8ppmである液状組成物を調製した。以上の液状組成物につき、容器内で酸素を遮断しつつ、環境光を遮蔽しない条件で25日間放置する一方、定期的に液状組成物をサンプリングし、高速液体クロマトグラフィーにより残存するシアニン色素の量を測定した。結果を図1に示す。
【0023】
図1の結果は、溶液状のシアニン色素を分解させる主因が溶存酸素であり、水性媒体をしてその常温常圧の大気環境下における酸素濃度を下回らせることによって、シアニン色素の残存率(%)、すなわち、配合したシアニン色素に対する残存シアニン色素の比率を改善し得ることを物語っている。図1の結果に見られるとおり、シアニン色素の残存率は溶存酸素の濃度が低下するにしたがって改善され、0.1ppm以下の酸素濃度では、実に、25日間放置しても、容器内で酸素が遮断されているかぎり、シアニン色素が全く分解しなかった。
【0024】
【発明の効果】
以上説明したとおり、この発明は、シアニン色素が水性媒体において分解する主因が溶存酸素であるという従来未知の独自の知見に基づくものである。安定にして取扱い易いこの発明の液状組成物は、医療分野における注射剤としての用途に加えて、化学及び分析化学の分野において、シアニン色素の収量や分析精度を改善するうえで極めて有用である。
【0025】
斯くも顕著な効果を奏するこの発明は、斯界に貢献すること誠に多大な、意義のある発明であると言える。
【図面の簡単な説明】
【図1】酸素濃度が異なる液状組成物におけるシアニン色素の残存率の変化を経時的に示す図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a composition containing an organic dye compound, and more particularly to a stable liquid composition containing a cyanine dye.
[0002]
[Prior art]
Root causes of disease include microbial infection, chemical exposure, radiation exposure, living environment, lifestyle, aging, genetic factors, etc. There are various. For example, in the case of microbial infection, not all living organisms invaded by microorganisms cause infection, and even when patients who are receiving similar treatment are treated for infection, Side effects can be significantly different. One of the causes is that the vitality of the living body is reduced at the cellular level. If the vitality of the living body is reduced at the cellular level, it is natural that the recovery of health is delayed, Side effects are strongly manifested. A cell activator is a drug for promoting the resistance and recovery of a living body to the pathogenesis at the cellular level by using such a patient in combination with other drugs as necessary. Currently, chlorophyll preparations, dye preparations, nucleic acid preparations, amino acid preparations, animal and plant extracts, etc. are used as cell activators. Of these, dye preparations exhibit remarkable effects at low doses and are effective. Has been used since the 1940s, mainly for burns and refractory skin ulcers.
[0003]
The pigment preparation is injected and administered intradermally, intramuscularly or intravenously according to the disease or symptom to be treated. At present, the dye preparation is only available in the form of a dry injection containing a cyanine dye, but the liquid preparation is not available because the cyanine dye is unstable in an aqueous medium. . Since the dry injection of cyanine dye has a relatively low solubility of cyanine dye in an aqueous medium, there is a problem that it takes time to prepare a solution of a predetermined concentration in a clinical site prior to use.
[0004]
[Problems to be solved by the invention]
In view of such a situation, an object of the present invention is to provide a stable liquid composition containing a cyanine dye.
[0005]
[Means for Solving the Problems]
In order to solve this problem, the present inventor diligently researched and searched, and found that the instability of the cyanine dye in the aqueous medium was caused by coexisting oxygen. Therefore, the present inventors paid attention to the oxygen concentration in the cyanine dye liquid composition, prepared various liquid compositions having different dissolved oxygen concentrations, and measured the remaining cyanine dye after leaving them for a certain period of time. As a result, in a liquid composition in which the concentration of dissolved oxygen is lower than the oxygen concentration in an atmospheric environment at normal temperature and pressure in an aqueous medium, it is difficult for the cyanine dye to decompose and to exist stably over a relatively long period of time. I found it.
[0006]
That is, the present invention provides the above-described problem by including a specific cyanine dye and an aqueous medium in which the cyanine dye is dissolved, and the concentration of dissolved oxygen in the atmospheric environment of the aqueous medium at normal temperature and pressure. The problem is solved by providing a liquid composition lower than.
[0007]
Further, the present invention solves the above-mentioned problem by a liquid that passes through a step of dissolving a specific cyanine dye in an aqueous medium and a step of lowering the oxygen concentration in the atmospheric environment at normal temperature and pressure using the aqueous medium. The problem is solved by providing a method for producing the composition.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
As described above, the present invention comprises a cyanine dye represented by the general formula 1 (hereinafter sometimes simply referred to as “cyanine dye”) and an aqueous medium in which the cyanine dye is dissolved, and dissolved oxygen. Relates to a liquid composition in which the concentration of is lower than the oxygen concentration in the atmospheric environment of the aqueous medium at normal temperature and pressure.
[0009]
[Chemical formula 2]
Figure 0005013325
[0010]
In the general formula 1, R represents an aliphatic hydrocarbon group. As the aliphatic hydrocarbon group for R, those having 1 to 12 carbon atoms are usually selected. Examples of the individual aliphatic hydrocarbon groups include a methyl group, an ethyl group, a propyl group, an isopropyl group, and butyl. Group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, tert-pentyl group, 1-methylpentyl group, 2-methylpentyl group, hexyl group, isohexyl group, 5-methylhexyl group, Examples include heptyl group, octyl group, nonyl group, decyl group, undecyl group, dodecyl group and the like. X in the general formula 1 is an appropriate counter ion, and usually, for example, fluorine ion, chlorine ion, bromine ion, iodine ion, perchlorate ion, periodate ion, hexafluorophosphate ion, antimony hexafluoride. Inorganic acid anions such as acid ions, hexafluorostannate ions, phosphate ions, borofluoride ions, tetrafluoroborate ions, thiocyanate ions, benzenesulfonate ions, naphthalenesulfonate ions, naphthalenedisulfonate ions, From organic acid anions such as p-toluenesulfonate ion, alkylsulfonate ion, benzenecarboxylate ion, alkylcarboxylate ion, trihaloalkylcarboxylate ion, alkylsulfate ion, trihaloalkylsulfate ion, nicotinate ion, aspartate ion, etc. Selected. Among these, as the cyanine dye in the liquid composition used as an injection, those having an R carbon number of 4 to 10, particularly 6 to 8 are particularly preferable because of their high affinity for cell membranes. A cyanine dye whose counter ion is an iodine ion is characterized in that the iodine ion exhibits a bactericidal action in vivo. Specific examples of the cyanine dye represented by the general formula 1 include, for example, those represented by the chemical formulas 1 to 3, and any of these can be used very advantageously in the present invention.
[0011]
[Chemical 3]
Figure 0005013325
[0012]
[Formula 4]
Figure 0005013325
[0013]
[Chemical formula 5]
Figure 0005013325
[0014]
The aqueous medium referred to in the present invention has water as an essential element, and if necessary, for example, alcohols such as methanol, ethanol, propanol and isopropanol, ketones such as acetone, and ethers such as diethyl ether In general, it means an aqueous medium in which one or more hydrophilic organic solvents including a sulfur-containing compound such as dimethyl sulfoxide are blended. As the aqueous solvent in the injection according to the present invention, purified water for injection is used alone, or purified water for injection and physiologically acceptable, for example, ethanol, propanol, isopropanol, diethyl ether, dimethyl sulfoxide, etc. It is desirable to use a mixed solution with a hydrophilic organic solvent.
[0015]
The liquid composition referred to in the present invention is an air in which one or more cyanine dyes represented by the general formula 1 are dissolved in such an aqueous medium, and the concentration of oxygen dissolved in the aqueous medium is normal temperature and atmospheric pressure. The range is below the oxygen concentration in the environment, usually 8 ppm or less, desirably 0.4 ppm or less, and more desirably 0.1 ppm or less. In the liquid composition having such an oxygen concentration, the cyanine dye is hardly decomposed even when exposed to ambient light such as natural light or artificial light during preparation or storage. In particular, a liquid composition having an oxygen concentration of 0.1 ppm or less hardly decomposes the cyanine dye as long as oxygen is blocked even when stored for a long time under conditions that do not block ambient light.
[0016]
Such a liquid composition is usually produced by the process of dissolving the cyanine dye in an aqueous medium and the process of lowering the oxygen concentration in the atmospheric environment at normal temperature and pressure using the aqueous medium. Can be prepared. In order to dissolve the cyanine dye in the aqueous medium, for example, a predetermined amount of the cyanine dye is added to an appropriate amount of the aqueous medium, and if necessary, dissolved with heating and stirring. Add aqueous medium until the concentration of is at a predetermined level. The liquid composition according to the present invention includes vitamins, amino acids, osmotic pressure regulators, buffers, which are commonly used for other drugs depending on the application, cell activators, as well as cyanine dyes, without departing from the object of the present invention. It does not prevent the addition of an agent, and further an oxygen scavenger.
[0017]
To from turning down the oxygen concentration in the atmospheric environment of normal temperature and normal pressure with an aqueous medium, for example, a liquid composition was prepared under reduced pressure, stored either oxygen another gas dissolved in the liquid composition Or a method in which the liquid composition is brought into contact with an oxygen scavenger is preferred. In order to replace oxygen dissolved in the liquid composition with another gas, in the liquid composition, for example, a relatively inert gas such as nitrogen or a rare gas such as neon, argon, krypton, or xenon is used. Just bubbling. In order to reduce the oxygen concentration using an oxygen scavenger, the liquid composition can be prepared, for example, by adding L-ascorbic acid, L-ascorbic acid stearate, sodium sulfite, sodium bisulfite, alphathioglycerin, sodium edetate, cysteine hydrochloride Citric acid, soybean lecithin, sodium thioglycolate, sodium thiomalate, sodium pyrosulfite, butylhydroxyanisole and the like may be added in appropriate amounts. These methods may be applied to a liquid composition containing a cyanine dye or an aqueous medium before the cyanine dye is dissolved.
[0018]
The liquid composition thus obtained is stored in a state in which it is sealed in a suitable container that can block oxygen. The material of the container is not particularly limited as long as it can hold the liquid composition in principle and can substantially block oxygen. Although depending on the application, the liquid composition is usually dispensed into containers such as glass ampoules and vials, sealed, and then sterilized by high-pressure sterilization or the like.
[0019]
The method of using the liquid composition according to the present invention will be described. The liquid composition according to the present invention is difficult to decompose cyanine dyes even when exposed to ambient light such as natural light or artificial light for a long time. It is extremely useful in various fields. The most important use is in the medical field, and injections with the liquid composition of the present invention are surgical, plastic surgery, plastic surgery, radiology, internal medicine, neurology, neurology, pediatrics, respiratory medicine, obstetrics and gynecology In the medical field such as otolaryngology, dermatology, urology, ophthalmology, anesthesiology, dentistry, etc. alone or in combination with other therapeutic agents, preventive agents, the immune system, hematopoietic system, endocrine system, cardiovascular system in the living body It activates the system, digestive system and nervous system at the cellular level. Furthermore, the injection according to the present invention has an action of suppressing oxidation of lipid components in the biological membrane. As an application in a field other than the medical field, in the field of chemistry and analytical chemistry, a remarkable effect is exhibited in improving the yield of cyanine dye and analysis accuracy. In the medical field, when the liquid composition according to the present invention is used as an injection, the usage and dosage are set according to conventionally known ones.
[0020]
Hereinafter, embodiments of the present invention will be described along examples.
[0021]
【Example】
<Liquid composition>
A solution obtained by dissolving 15 g of glucose in 200 g of purified water for injection and a solution obtained by dissolving 15 mg of platonins represented by Chemical Formula 3 in 85 g of purified water for injection are mixed to form a liquid composition, which is dissolved. Nitrogen gas was bubbled until the oxygen concentration reached about 0.1 ppm, and 1 ml each was dispensed into a brown ampule. The ampule was sealed under a nitrogen stream, and then sterilized under high pressure. When measured by a conventional method, the oxygen concentration in the liquid composition of this example was 0.097 ppm.
[0022]
For comparison, a liquid composition having a dissolved oxygen concentration of 0.47 ppm, 0.49 ppm or 8.8 ppm was prepared by shortening the bubbling time or omitting the bubbling. The above liquid composition is left to stand for 25 days under the condition of blocking oxygen in the container and not blocking ambient light, while the liquid composition is periodically sampled and the amount of cyanine dye remaining by high performance liquid chromatography Was measured. The results are shown in FIG.
[0023]
The result of FIG. 1 shows that the main cause of decomposing the solution cyanine dye is dissolved oxygen. By using an aqueous medium to lower the oxygen concentration in the atmospheric environment at normal temperature and pressure, the residual ratio of cyanine dye (% ), I.e., the ratio of residual cyanine dye to formulated cyanine dye can be improved. As can be seen from the results of FIG. 1, the residual ratio of cyanine dye is improved as the concentration of dissolved oxygen is decreased. When the oxygen concentration is 0.1 ppm or less, oxygen remains in the container even if left for 25 days. As long as it was blocked, the cyanine dye did not decompose at all.
[0024]
【Effect of the invention】
As described above, the present invention is based on a unique knowledge that has not been known so far that dissolved oxygen is the main cause of the degradation of cyanine dyes in an aqueous medium. The liquid composition of the present invention which is stable and easy to handle is extremely useful in improving the yield and analytical accuracy of cyanine dyes in the fields of chemistry and analytical chemistry, in addition to the use as an injection in the medical field.
[0025]
It can be said that this invention having such remarkable effects is a very significant invention that contributes to the world.
[Brief description of the drawings]
FIG. 1 is a graph showing changes in residual ratio of cyanine dyes over time in liquid compositions having different oxygen concentrations.

Claims (4)

一般式1で表されるシアニン色素と、そのシアニン色素を溶解する水性媒体とを含んでなり、溶存酸素の濃度が0.1ppm以下である液状組成物。
Figure 0005013325
一般式1において、Rは炭素数4乃至10の脂肪族炭化水素基を、また、X沃素イオンを表す。
A liquid composition comprising a cyanine dye represented by formula 1 and an aqueous medium in which the cyanine dye is dissolved, wherein the dissolved oxygen concentration is 0.1 ppm or less.
Figure 0005013325
In formula 1, R is an aliphatic hydrocarbon group having 4 to 10 carbon atoms, also, X - represents an iodide ion.
水性媒体が精製水である請求項1記載の液状組成物。Claim 1 Symbol placement of the liquid composition the aqueous medium is purified water. 注射剤としての請求項1又は2記載の液状組成物。The liquid composition according to claim 1 or 2 as an injection. 一般式1で表されるシアニン色素を水性媒体に溶解する工程と、該水性媒体をしてその酸素濃度を0.1ppm以下とする工程とを経由する請求項1乃至のいずれかに記載の液状組成物の製造方法。The method according to any one of claims 1 to 3 , wherein the process goes through a step of dissolving the cyanine dye represented by the general formula 1 in an aqueous medium and a step of setting the oxygen concentration of the aqueous medium to 0.1 ppm or less. A method for producing a liquid composition.
JP2000315975A 2000-10-16 2000-10-16 Liquid composition Expired - Lifetime JP5013325B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000315975A JP5013325B2 (en) 2000-10-16 2000-10-16 Liquid composition
KR1020010063186A KR20020030022A (en) 2000-10-16 2001-10-13 Liquid composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000315975A JP5013325B2 (en) 2000-10-16 2000-10-16 Liquid composition

Publications (3)

Publication Number Publication Date
JP2002121416A JP2002121416A (en) 2002-04-23
JP2002121416A5 JP2002121416A5 (en) 2007-11-29
JP5013325B2 true JP5013325B2 (en) 2012-08-29

Family

ID=18794989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000315975A Expired - Lifetime JP5013325B2 (en) 2000-10-16 2000-10-16 Liquid composition

Country Status (2)

Country Link
JP (1) JP5013325B2 (en)
KR (1) KR20020030022A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397139B1 (en) * 2009-01-29 2014-09-17 Hayashibara Co., Ltd. Anti-neurodegenerative disease agent
JPWO2010087315A1 (en) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 Anti-Alzheimer's disease agent
WO2010087313A1 (en) * 2009-01-29 2010-08-05 株式会社林原生物化学研究所 Neurite elongation stimulator
JP6581374B2 (en) * 2015-03-24 2019-09-25 株式会社日本触媒 Method for storing or using a composition comprising an oxocarbon-based compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4580479B2 (en) * 1998-12-21 2010-11-10 株式会社林原生物化学研究所 Anti-HIV infection agent

Also Published As

Publication number Publication date
JP2002121416A (en) 2002-04-23
KR20020030022A (en) 2002-04-22

Similar Documents

Publication Publication Date Title
RU2192249C2 (en) Paracetamol-base liquid stable composition and method of its preparing
EP2307056B1 (en) Stabilized aqueous formulation containing paracetamol
JPH05506245A (en) Pharmaceutical composition of florfenicol
JP4861162B2 (en) Paracetamol liquid formulation for injection
DE602005014393D1 (en) STABLE PHARMACEUTICAL COMPOSITIONS OF ANTITUMOROUS PLATINUM (II) AGENTS
JP6892494B2 (en) Aqueous formulation containing paracetamol and ibuprofen
PT1609481E (en) Injectable pharmaceutical compositions comprising sodium diclofenac, beta-cyclodextrin and a polysorbate
WO2013144814A1 (en) Stable ready-to-use pharmaceutical composition of pemetrexed
KR20160014592A (en) Pharmaceutical formulations for subcutaneous administration of furosemide
CN1274293C (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
UA104381C2 (en) Stable composition of paracetamolum prepared to application for injections
JP5013325B2 (en) Liquid composition
RU2362557C2 (en) Pharmaceutical composition of vinflunine intended for parenteral administration, way of reception and application
JP2009143922A (en) Injection product
CN110269837B (en) Naloxone hydrochloride injection and preparation method thereof
JP2010077104A (en) Aqueous injection solution of 3-methyl-1-phenyl-2-pyrazoline-5-one
CN116270443A (en) Fu Nuola raw fumaric acid injection and preparation method thereof
CA3045794A1 (en) Levothyroxine liquid formulations
HU179989B (en) Process for preparing pharmacological compositions containing r-/+/-1-/1-phenyl-ethyl/-1h-imidazol-5-carboxylic acid ethyl ester for intravenous administration
CN102204908B (en) Pharmaceutical composition containing edaravone compound, and preparation method thereof
CN103027890B (en) Ibuprofen medicine composition for injection
JPH0517431A (en) Stabilized cysteine solution
JP3535537B2 (en) Intravenous injection
JPWO2005014009A1 (en) Glycyrrhizin high-concentration formulation
TWI546087B (en) Containing aqueous preparations of acetaminophen and ibuprofen

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111206

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120515

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20120528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120528

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150615

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5013325

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250